Category - Executive Moves

Executive Moves

Roth promotes Yasmeen Rahimi to co-head biotech research

Roth Capital Partners promoted Yasmeen Rahimi, managing director and senior research analyst, to the position of co-head of biotechnology research.

March 28, 2019

Executive Moves

BriaCell Therapeutics names two biopharma experts to its board

BriaCell Therapeutics (TSV-V:BCT; OTCQB:BCTXF) appointed Dr. Rebecca Taub and Vaughn Embro-Pantalony as directors, and current board members Dr. Saeid Babaei, Rahoul Sharan, and Martin Schmieg have resigned, effective...

March 18, 2019

Executive Moves

C4 Therapeutics appoints Adam Crystal as CMO

C4 Therapeutics appointed a new CMO, Dr. Adam Crystal, to oversee clinical development of its pipeline of protein degrader-based therapeutics.

March 14, 2019

Executive Moves

BioSig appoints Barry Keenan as VP of engineering

BioSig Technologies (NASDAQ:BSGM) named Barry Keenan as VP of engineering to head up the company’s advanced product development.

March 6, 2019

Executive Moves

Roth names Tony Butler as head of biotech research

Roth Capital Partners appointed Charles “Tony” Butler as a managing director, senior research analyst and head of biotechnology research, and a partner.

February 21, 2019

Executive Moves

IntelGenx names Rodolphe Obeid as VP of operations

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) appointed Dr. Rodolphe Obeid as VP of operations to oversee manufacturing, packaging, facilities and maintenance, production planning and supply chain management.

February 8, 2019

Executive Moves

Maxim names Mario Leite as a senior healthcare banker

Maxim Group expanded its healthcare investment-banking group with the appointment of Mario Leite as a managing director.

February 6, 2019

Executive Moves

BioSig appoints John Kowalski as VP of sales

BioSig Technologies (NASDAQ:BSGM) named John Kowalski as VP of sales to lead the commercial launch of the PURE EP signal acquisition and processing system, which is designed to improve the diagnosis and treatment of...

February 5, 2019

Executive Moves

Ocutrx Vision names Dr. Linda Lam as chief scientific and strategy officer

Closely-held Ocutrx Vision Technologies appointed Dr. Linda Lam as chief scientific and strategy officer to guide new technology development, and help align current and future R&D efforts, industry trends and growth...

January 16, 2019

Executive Moves

Prometic names Prof. Simon Best as interim CEO

Prometic Life Sciences (TSX:PLI; OTCQX:PFSCF) named Prof. Simon Best as interim CEO, effective immediately, succeeding Pierre Laurin, who has stepped down from his management and board responsibilities.

December 20, 2018

Category - Executive Moves

Roth promotes Yasmeen Rahimi to co-head biotech research

BriaCell Therapeutics names two biopharma experts to its board

C4 Therapeutics appoints Adam Crystal as CMO

BioSig appoints Barry Keenan as VP of engineering

Roth names Tony Butler as head of biotech research

IntelGenx names Rodolphe Obeid as VP of operations

Maxim names Mario Leite as a senior healthcare banker

BioSig appoints John Kowalski as VP of sales

Ocutrx Vision names Dr. Linda Lam as chief scientific and strategy officer

Prometic names Prof. Simon Best as interim CEO

General

More